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The acute-phase response of the plasma proteins to tissue injury and inflammation 
is  a  nonspecific  phenomenon  (1,  2).  However,  recent  clinical  work  in  man,  using 
precise  immunoassays,  has  shown  that  not  all  acute-phase  proteins  behave  in  a 
completely nonspecific way. For example, there are highly significant differences in 
the  levels  of C-reactive  protein  (CRP),  the  classical  acute-phase  reactant,  and  of 
serum amyloid A protein (SAA), the precursor of AA type amyloid fibrils, in different 
diseases  (3,  4).  Patients with active rheumatoid arthritis usually have high SAA  (4) 
and CRP (5) levels, which correlate closely with other clinical and laboratory indices 
of disease  activity  (6,  7).  In  contrast,  patients  with  systemic  lupus  erythematosus 
(SLE)  generally fail to mount a  major acute-phase response of CRP  (8)  or SAA (4), 
despite the presence of severe active disease. These patients, however, remain capable 
of producing CRP and SAA, and do so, for example, when they acquire intercurrent 
microbial infections (8). 
Two  distinct  mechanisms  may underlie  such  notable  differences  in  acute-phase 
response.  First,  the  disease  process of SLE per se may not  stimulate production  of 
these particular  acute-phase proteins.  Second,  those  individuals  who manifest  SLE 
may be "low acute-phase responders," possibly on a genetic basis, to immune complex 
and autoantibody-mediated  inflammation. The first explanation  seems unlikely, as 
inflammation  and  tissue  destruction  on  the  scale  seen  in  active  SLE  are  usually 
powerful stimuli to acute-phase protein synthesis  (1,  2), as are the active or passive 
formation of immune complexes in vivo (9,  10). 
To investigate these questions further, we have studied the acute-phase response of 
serum amyloid P component (SAP) in two mouse models of spontaneous autoimmune 
disease. Mouse CRP is an acute-phase reactant, but is present only in trace amounts 
and is not easily measured;  SAP, however, is closely related to CRP and is a  major 
acute-phase protein in mice (11,  12). We report here for the first time that  (NZB × 
NZW)F1 (NZB ×  W) mice, which develop a chronic inflammatory disease resembling 
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human SLE (13), completely fail to mount any acute-phase response of SAP during 
evolution of their pathology. In contrast MRL lpr/lpr (MRL/1)  mice, which develop 
a more rapidly progressive lupus-like autoimmune disease including polyarthritis and 
the  presence  of  serum  rheumatoid  factors  (14,  15),  display  high  levels  of  SAP 
correlating with the progress and severity of their disease. 
Materials and Methods 
Mice.  BALB/c and MRL/1 mice (The Jackson Laboratories, Bar Harbor, ME) were bred 
at  the  CIBA-GEIGY animal  research  center,  Sisseln,  Switzerland.  These  mice  and  female 
NZB ×  W animals (Bomholtgard, Denmark) were housed in the same room and fed the same 
diet from the age of 4 wk. 
Blood samples.  Groups of 5-16 mice were sequentially bled at  the intervals shown in the 
figures,  and  sera  were  stored at  -20°C  before being tested  individually  at  the end  of the 
experiment. 
Assays.  The concentration of  SAP in serum was measured by electroimmunoassay calibrated 
with the isolated pure protein (16). Antibodies to single stranded DNA (ssDNA)  and to double 
stranded DNA (dsDNA) were measured separately by enzyme-linked immunoabsorbent assay 
(17), using as reference a serum pool from old female NZB ×  W mice, (arbitrary value 200 U/ 
ml). Circulating immune complexes (CIC) were sought by solid-phase C 1  q binding assay (18), 
using an  alkaline  phosphatase-labeled  rabbit  anti-mouse  Ig~  (specific  for heavy and  light 
chains) (N. L. Cappel Laboratories, Cochranville, PA) and standards of heat-aggregated mouse 
IgG. Proteinuria was assessed on random samples of  urine using Rapignost sticks (Behringwerke 
AG, Marburg, Federal  Republic of Germany) calibrated  with mouse serum albumin  (N.  L. 
Cappel Laboratories). 
Acute-phase Responses.  Groups of five NZB ×  W  and BALB/c mice at  1, 3, 6, and 9 mo of 
age received per mouse either  100 #g lipopolysaccharide  (LPS)  W  from Salmonella enteritidis 
(Difco Laboratories, Detroit, MI) by intraperitoneal  injection or 0.5 ml of 10% wt/vol casein 
solution (vitamin-free casein, ICN Nutritional Biochemicals, Cleveland, OH) by subcutaneous 
injection. Each mouse was bled before and 24, 48, and 72 h after the injection to provide serum 
for assay of SAP. 
Results 
With increasing age the concentrations of antibodies to ssDNA and dsDNA as well 
as  the  level of CIC increased  in both  NZB  ×  W  and  MRL/I  mice  (Fig.  1).  These 
serological changes correlated with the appearance and progression of clinical disease, 
exemplified  by proteinuria,  and  the  tempo of their  progress was more rapid  in the 
MRL/I  mice,  so that  none survived  to 40 wk.  In the  NZB  ×  W  mice there  was a 
notable  absence  of any  acute-phase  response  of  SAP,  whereas,  in  contrast,  the 
MRL/I mice showed a  dramatic rise in SAP levels, increasing from 50 +_ 10/Lg/ml at 
6 wk to 420 -+ 96 #g/ml at  25 wk (Fig.  1).  Normal, untreated  BALB/c mice, which 
served  as controls,  did  not  develop serological abnormalities  and showed no acute- 
phase response (Fig.  1). 
The capacity of NZB ×  W  mice at any age between  1 and 9  mo to mount acute- 
phase  responses  to  inflammatory  stimuli  other  than  their  underlying  diseases  was 
demonstrated after injection of LPS or casein  (Fig. 2). In both cases, the behavior of 
SAP was similar to that seen in control BALB/c mice. 
Discussion 
The  different  patterns  of acute-phase  response  seen  in  different  human  diseases 
provide the basis for some useful applications of acute-phase protein measurement in 
clinical practice, but their underlying mechanisms are not known (2-5). The present 1270  RORDORF  ET  AL.  BRIEF  DEFINITIVE  REPORT 
800 
600 
400 
200 
MRL/I  [1280) 
•  ~--e  • 
/ i'-.\ 
i:  "',)\ 
:"  I  ~,  v 
....l  -,, 
I 
/.L  i 
..-~  i 
600 I 
400 
200 
(NZBxNZW)F1  (1180[ 
/ 
/ 
/ 
? ( 
/ 
~'~."  ......  L  iiiiiiiii  i  iiiiiiiii 
200 I  BALB/c 
0 /  I~;~.~11" .........................  ~]J  ~ 
0  10  20  30  40  AGE 
(weeks) 
FIG.  1.  Serum  levels  of SAP  (  ),  CIC  (---),  anti-ssDNA  antibodies  (-.-),  anti-dsDNA 
antibodies ( ..... ), and quantity of proteinuria (  ) in autoimmune and control mice. Each point 
represents the arithmetic mean  of 16  female  (NZB  ×  NZW)F1,  6  male MRL/I,  and  10  female 
BALB/c mice, respectively. Scale denotes 10  -1/lg/ml for CIC,/~g/ml for SAP, mg/dl for proteinuria, 
and U/ml of anti-DNA antibodies. 
observations of different  acute-phase  responses of SAP,  a  protein  closely related  to 
CRP, in different mouse strains that spontaneously develop autoimmune, lupus-like, 
and  rheumatoid  arthritis-like  diseases may help  to elucidate  these phenomena and 
also the control mechanisms of the acute-phase response in general. 
CRP, SAP, and SAA are all synthesized by hepatocytes (19), and there is evidence 
that  interleukin  1,  derived  from mononuclear phagocytes,  may play an  important 
role in the induction  of their increased  production  (reviewed in  19). Prostaglandins 
may also be involved, as they can stimulate acute-phase responses both in the rabbit 
and man (20). The murine strains investigated here provide the opportunity to dissect 
the processes that  underlie  such  differences in  the acute-phase response in  terms of 
production of mediators, such as interleukin  1 and prostaglandins, and responsiveness 
to different stimuli by macrophages and hepatocytes. It is intriguing that injection of 
prostaglandin  E1  has a  significant  protective effect both in  NZB  ×  W  and  MRL/1 
mice (21-23). 
CRP and SAP are both ligand-binding proteins. CRP can react with a wide range 
of materials  of exogenous  and  autogenous  origin,  including  phospholipids,  nucleic 
acids,  and cationic intracellular  proteins  (reviewed in  2,  3), whereas SAP is able to 
bind  fibronectin  and  C4-binding  protein  (24).  SAA  is  an  apolipoprotein  of high RORDORF ET AL.  BRIEF DEFINITIVE REPORT  1271 
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FIG. 2.  Acute-phase responses of SAP to injection of LPS (A, C)  or casein (B, D)  in  (NZB x 
NZW)Ft (C, D) and BALB/c mice (A, B). Each point represents the arithmetic mean of five female 
mice, groups of which were tested at the age of 1 (  ), 3 ( ..... ), 6 (- - -), and 9 mo (-.-). 
density lipoprotein  (reviewed  in  19), and  this  class of lipoprotein  has recently been 
shown to form complexes with gram-negative bacterial endotoxin in the plasma (25). 
The rate of production and the circulating level of these proteins may thus influence 
the outcome of infective or noninfective inflammation or tissue damaging events and 
modify clinical patterns of disease. 
We have previously reported  (11) that normal resting levels of SAP are genetically 
determined  in mice.  The present  finding of failure of NZB  X  W  mice to mount  an 
acute-phase SAP response to progress of their disease closely resembles  the situation 
with regard to CRP in human SLE, whereas the response of MRL/I mice, in contrast, 
parallels  that  seen  in  human  rheumatoid  arthritis  or those  exceptional  individuals 
with SLE whose patterns of disease alters to become more like systemic vaseulitis  (5, 
8). These analogies of response raise the possibility that production of human acute- 
phase  proteins  in  response  to some stimuli  may also be under genetic  control,  and 
suggest  that  this  could  contribute  towards  individual  susceptibility  to  particular 
autoimmune  or  other  chronic  inflammatory  disease.  Further  exploration  of these 
phenomena in the mouse models should therefore be both of academic interest  and 
clinically relevant. 
Summary 
The acute-phase  plasma  protein  response to disease  activity in murine  models of 
autoimmune lupus-like disease was investigated by measurement of the concentration 1272  RORDORF  ET  AL.  BRIEF DEFINITIVE REPORT 
of serum amyloid P  component  (SAP) in NZB  X  W  and MRL/I  mice. The levels of 
SAP, which is a  major acute-phase protein in mice, did not rise at all in response to 
progression  of disease  in  NZB  ×  W  mice  between  the  ages  of  1  and  9  mo.  This 
resembles the behavior of acute-phase proteins such as C-reactive protein and serum 
amyloid A  protein  in  human  systemic lupus  erythematosus,  and just  as in  human 
lupus,  where  the  occurrence  of intercurrent  microbial  infection  can  stimulate  an 
acute-phase response, so injection of bacterial lipopolysaccharide or casein into the 
NZB  ×  W  mice  stimulated  "normal"  acute-phase  SAP  production.  In  marked 
contrast,  MRL/1  mice  developed greatly increased  levels of SAP, which  correlated 
closely with  progression of their pathology as they aged.  The  disease profile of the 
MRL/I  strain  includes rheumatoid  factors  and  spontaneous  polyarthritis and  their 
SAP response resembles the behavior of acute phase proteins in human  rheumatoid 
arthritis. Different patterns of acute-phase response in different autoimmune disorders 
may thus  be a  reflection of the genetic predisposition to particular diseases and/or 
contribute to their pathogenesis. The existence of animal counterparts for the various 
clinical patterns of human acute-phase protein production will assist in experimental 
investigation of the underlying mechanisms  and of the biological role of the acute- 
phase response. 
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